Daxor Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Funds from Operations
1,369.00
1,320.80
18,250.40
1,729.10
2,713.90
977.10
Changes in Working Capital
922.10
1,025.20
91.60
408.10
446.80
338.50
Net Operating Cash Flow
2,291.10
295.60
18,342.00
1,321.00
2,267.20
1,315.60
Purchase/Sale of Investments
12,208.50
-
2,448.30
-
-
Net Investing Cash Flow
11,333.70
-
2,448.30
-
-
Cash Dividends Paid - Total
204.50
119.80
154.10
114.00
112.10
Issuance/Reduction of Debt, Net
9,567.30
1,111.30
17,511.20
1,043.40
1,532.80
Net Financing Cash Flow
9,042.70
295.60
18,525.60
1,592.70
1,172.50
Net Change in Cash
-
-
2,264.70
271.70
1,094.60
Free Cash Flow
2,291.10
295.60
18,342.00
1,321.00
2,267.20
Change in Capital Stock
320.10
695.90
860.30
435.30
248.20

About Daxor

View Profile
Address
Empire State Building
New York New York 10118
United States
Employees -
Website http://www.daxor.com
Updated 07/08/2019
Daxor Corp. is a biotechnology company which develops and manufactures BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage; and andrology services, such as semen analysis, sperm washing and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in New York, NY.